The market for GLP-1 weight loss drugs could exceed $100 billion by 2030, analysts say
Robert F. Kennedy Jr., a prominent critic of the food and pharmaceutical industries, discussed his views regarding GLP-1 weight loss drugs in a televised broadcast.
Kennedy, who was nominated by President-elect Donald Trump to lead the Department of Health and Human Services (HHS), said that lifestyle changes — specifically healthy eating and avoiding obesity — should be the primary approach to weight management.
Kennedy said GLP-1 drugs should be limited to a secondary role, in the broadcast.
Drugs with a glucagon-like peptide-1 (GLP-1) classification such as Novo Nordisk’s Wegovy and Ozempic and Eli Lilly’s Zepbound and Mounjaro, help in the regulation of digestion, appetite, and sugar which aid in weight loss.
Kennedy’s comments about GLP-1 weight loss drugs attracted the attention of Wall Street, especially since he has voiced concerns about the popularity of these drugs and their impact on public health.
After his nomination in November, Pfizer, a vaccine maker, stock fell by 2.6%, along with BioNTech (7.1%) and Moderna (5.6%) amid Kennedy’s publicized disdain for vaccinations.
Kennedy, a staunch vaccine skeptic, once felt the wrath of his famous family members after they “united” against his “dangerous” views on health, said cousin, Caroline Kennedy, the U.S. ambassador to Australia.
Source :https://www.ibtimes.com/rfk-jr-says-people-should-eat-better-instead-using-weight-loss-drugs-3755253
